Abstract

Molecular imaging can allow the non-invasive assessment of biological and biochemical processes in living subjects. Such technologies therefore have the potential to enhance our understanding of disease and drug activity during preclinical and clinical drug development, which could aid decisions to select candidates that seem most likely to be successful or to halt the development of drugs that seem likely to ultimately fail. Here, with an emphasis on oncology, we review the applications of molecular imaging in drug development, highlighting successes and identifying key challenges that need to be addressed for successful integration of molecular imaging into the drug development process.

Author affiliations

1. The Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, California 94305-5427, USA.
2. Biomedical Imaging, Genentech, South San Francisco, California 94080-4990, USA.
3. Global Drug Discovery, Bayer Schering Pharma, 13353 Berlin, Germany.
4. Department of Bioengineering, Stanford University School of Medicine, Stanford, California 94305-5427, USA.

Correspondence to: Sanjiv S. Gambhir^1,4 Email: sgambhir@stanford.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.